Based on this evidence, we select CXCL10, CXCL11, and IFNG as rational proof-of-concept candidates for proposing a gene-therapeutic approach that remodels the TME by inducing tumour-intrinsic expression of immunostimulatory cytokines. The gene discussed is CXCL10; the disease is neoplasm.